Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, novembre 13
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Moderna Inc
MRNA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$226.43
-4.92
-2.13%
Dern. MÀJ: Nov 13, 12:05 PM
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
PRO
Pourquoi cela bouge-t-il ?:
Moderna shares are trading lower. Investors may be taking profit after the ...
Résultats:
Les résultats Q3 2026 ont été publiés le ven. nov. 6th, avant l'ouverture du marché
Conférence téléphonique:
La conférence téléphonique la plus récente a commencé à 8:00 AM, il y a 7 jours
Cliquez pour voir la webdiffusion
Moderna Financials
Moderna (MRNA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Moderna Analyst Day: Details Strategic Shift Toward Oncology and Enhanced Production Capabilities
Moderna raises its 2026 revenue forecast to 15%-25% and accelerates oncology investments, expanding its mRNA platform into new therapies.
Vandana Singh
Moderna Stuns Wall Street With Surprise Profit, Raises Outlook
Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
Vandana Singh
PRO
Moderna Raises FY2026 Sales Guidance from $2.138B to $2.236B-$2.430B vs $2.102B Est
Moderna (NASDAQ:MRNA) raises FY2026 sales outlook from $2.138 billion to $2.236 billion-$2.430 billion vs $2.102 billion estimate.
Benzinga Newsdesk
PRO
Moderna Q3 EPS $0.38 Beats $(1.26) Estimate, Sales $1.313B Beat $885.051M Estimate
Moderna (NASDAQ:MRNA) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $(1.26) by 130.16 percent. This is a 174.51 percent increase over losses of $(0.51) per share from the
Benzinga Newsdesk
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Moderna reports Q3 earnings Friday, with analysts expecting a $1.25 loss per share and $890M revenue; shares fell 6.6% after vaccine approvals.
Avi Kapoor
Stock Market: Will S&P 500 Open Up or Down Today?
Will the S&P 500 open higher? Polymarket odds hit 62% as Wall Street eyes jobs data and a tech rebound.
Rishabh Mishra
